Found: 5
Select item for more details and to access through your institution.
Changes in Inflammatory Biomarkers and Baseline Variables After Switching to Dolutegravir/Lamivudine(DTG/3TC) in 2 Randomized Clinical Trials of Virologically Suppressed Adults: 48-Week Pooled Analysis.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 272
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/ Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 271
- By:
- Publication type:
- Article
Do people living with HIV discuss adherence barriers with their HIV care providers? A comparison of findings from South Korea and other selected countries in the Asian region.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 267
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/ Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Aged ≥50 Years: Pooled Results From the TANGO and SALSA Studies.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 273
- By:
- Publication type:
- Article
Week 48 metabolic health after switch to DTG/3TC vs CAR by baseline regimen (SALSA).
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S300
- By:
- Publication type:
- Article